David Werner and Nathan Berman are behind the historic project that appears to have serious structural concerns.

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue ...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028. Management's attempt to solve the issue has ...

CHONGQING, CHINA - APRIL 23: In this photo illustration, the logo of Pfizer Inc. is displayed on a smartphone screen, with a stock market chart visible in the background, reflecting trading activity ...

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...